PINNED
PINNED
Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
Articles
Imaging In-Depth Focus 2020
The articles in this in-depth focus discuss the difficulties in deciding what information to capture when imaging three-dimensional (3D) cell models and the use of non-invasive imaging techniques to discover small molecule drugs to control protein translation.
Immuno-oncology In-Depth Focus 2020
This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.
Screening In-Depth Focus 2020
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).
Drug Target Review – Issue 2 2020
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Empty phage viruses as a method to combat influenza
A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
Chemical formulas relevant to COVID-19 drug targets
Find several chemical formulas for potential COVID-19 therapeutics and drug targets currently in development here.
Can a computer help us find a treatment for COVID-19?
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
Utilising an interleukin-12 plasmid: a novel COVID-19 vaccine
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
Begin with the end in mind: designing synthetic antibiotics with a universal mechanism of action
James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
Intravenous immunoglobulins, hyperimmunes and pandemic viruses
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Developing respiratory therapeutics for prophylaxis and treatment
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
Cytokine storms: a major killer in patients with severe COVID-19 infection
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
Natural peptides versus COVID-19
Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
Histone deacetylase 2 (HDAC2) regulates pathological response of inflammatory monocytes: a potential target of adjuvant therapies for COVID-19 infection
Histone deacetylase 2 (HDAC2) plays a key role in the regulation of inflammatory response in monocytes so could be a target for COVID-19, argue Dr Rosa Maria Tordera and Maria Cortes.
Developing immunotherapies for hard-to-treat cancers
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
